Objective: The aim of the study was to determine the effect of menopausal hormone therapy on incident hypertension in the two Women's Health Initiative hormone therapy trials and in extended postintervention follow-up.
T he effect of hormone therapy on the development of secondary hypertension in postmenopausal women remains controversial. Results from early clinical trials showed that postmenopausal hormone use had minimal or no effect on blood pressure, 1 although one such trial showed that younger age was associated with a treatmentassociated rise in systolic blood pressure. 2, 3 Results from retrospective and observational studies have been inconsistent with respect to associations between hormone therapy and blood pressure. [4] [5] [6] A recent large cohort study, however, showed a positive association between hormone therapy use and hypertension diagnosis that was more pronounced with younger age. 7 Recent data from a large randomized trial also suggest that dose and route of administration may matter; in that trial both lower oral dose and transdermal route of estrogen were not associated with an increase in blood pressure. 8 The Women's Health Initiative (WHI) included two randomized double-blind, placebo-controlled trials of hormone therapy (conjugated equine estrogens [CEE] in women with prior hysterectomy and CEE plus medroxyprogesterone acetate [MPA] in women with intact uteri) in relation to chronic disease incidence, including cardiovascular events and markers of cardiovascular health, among postmenopausal women. Both arms of the trial showed an approximate 1 mm Hg increase in systolic blood pressure at year 1 among women who received hormones, which persisted during follow-up 9, 10 ; this finding has since been confirmed by subsequent analysis. 11 Diastolic blood pressure did not differ at year 1 between intervention and placebo groups in the CEEalone or CEE plus MPA trials.
WHI results indicated that age and time since menopause onset may be important factors when interpreting the effect of hormone use on cardiovascular health. Women who took hormones in the CEE plus MPA trial had no increase in coronary events if they were within 10 years of the onset of menopause (hazard ratio [HR] ¼ 0.90) but a significant increase if they were 20 years past menopause (HR ¼ 1.52). 12 In the CEE-alone trial, women aged 50 to 59 years, who were assigned to estrogen, were less likely to experience a coronary event than women assigned to placebo (HR 0.60), 13 and this effect persisted through the post-trial follow-up period as initially and later reported (HR ¼ 0.59, HR ¼ 0.65). 13, 14 On the contrary, in both trials, younger and older women had similar treatment-associated increases in the risk of stroke. Thus, we sought to determine the effect of CEE alone and CEE plus MPA on the development of hypertension in the WHI during the intervention and postintervention phases, with attention to possible differences by age group or years since menopause onset. The effect of hormone therapy on rates for self-report of a physician's diagnosis of ''hypertension or high blood pressure requiring pills'' as an endpoint has not previously been reported and is our primary research question.
Our use of self-reported treatment for hypertension, which is included in some guidelines as an appropriate indicator for hypertension, 15 complements findings of a WHI publication on the effect of hormone therapy and mean blood pressure.
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A definition of hypertension based on high blood pressure measured on a single annual occasion is not consistent with clinical practice and may overestimate incidence. Consequently, we investigate this composite endpoint (self-report of hypertension or blood pressure 140/90 mm Hg) as a secondary endpoint.
WHI post-trial results for hypertension diagnoses have not been previously reported, and age may be an important factor determining cardiovascular risks and benefits associated with HT use. We report data on hypertension diagnosis for the intervention and postintervention periods for both the EþP and E-alone arms of the WHI Trial. This preplanned analysis had three objectives: (1) to assess the effect of CEE alone and CEE plus MPA, compared with placebo, on incident diagnoses of hypertension during the intervention; (2) to assess the long-term (postintervention) effects of the CEE alone and CEE plus MPA interventions on hypertension diagnoses; (3) to determine if age or time since menopause onset modified the effects of hormone therapy on incident hypertension during the intervention and postintervention periods METHODS Details of the study design have previously been published. 13, 16 Briefly, postmenopausal women aged 50 to 79 years were recruited at 40 US clinical centers between 1993 and 1998 for the CEE trial and the CEE plus MPA trial. Women were eligible if they were not taking hormone therapy, did not have a history of breast cancer or other cancer within 10 years (except nonmelanoma skin cancer), and had an anticipated survival of at least 3 years. Study participants provided informed consent in a document approved by local institutional review boards and were randomly assigned to receive oral CEE, 0.625 mg/d (Premarin; Wyeth Pharmaceuticals, Madison, NJ) or CEE plus 2.5 mg oral MPA (Prempro, Wyeth Ayerst, Philadelphia, PA), depending on hysterectomy status, or matching placebo. A total of 10,739 women were randomly assigned to receive CEE alone or placebo, and 16,608 to receive CEE plus MPA or placebo. Participants were excluded if they had selfreported at baseline ever taking pills to treat high blood pressure or hypertension, or were using antihypertension medications at their baseline medication inventory. The remaining participants were included in the analysis of the CEE-alone trial (n ¼ 6,342) and CEE plus MPA trial (n ¼ 11,673).
The postintervention phase began on July 8, 2002 for the CEE plus MPA trial and on March 1, 2004 for the CEE trial and ended on March 31, 2005 for both trials' in-clinic visit assessments, resulting in 2.6 and 1.0 years of postintervention follow-up, respectively. Subsequent participant follow-up through September 30, 2010 required additional written consent that was obtained on 83% and 78% of surviving participants in the CEE plus MPA and CEE trials, respectively.
Incident hypertension
Incident hypertension, the primary endpoint, was defined as self-report of treated hypertension and collected semiannually. Specifically, participants were asked, ''Since the date given on the front of this form, has a doctor prescribed any of the following pills or treatments?'' The choices included ''pills for high blood pressure or hypertension.'' Those who self-reported a prior history of treated hypertension or who were using antihypertensive medications at baseline were not eligible to be classified with incident SWICA ET AL disease and were excluded. A subsequent analysis was carried out to confirm the robustness of the primary endpoint with incident hypertension defined as either self-report of treated hypertension or blood pressure 140/90 mm Hg at least one of the annual follow-up clinic visits; blood pressure was measured at annual follow-up visits through the protocolspecified termination date (March 31, 2005) . Analyses of this secondary composite endpoint are presented in the Supplemental Digital Content, http://links.lww.com/MENO/A286. To investigate the whether the effect of hormone therapy on incident hypertension (primary endpoint) dissipated after the intervention had ended, summary statistics are also presented for the postintervention period that includes extended followup. Blood pressure was not collected during extended followup, so a similar analysis for the composite endpoint could not be performed for extended follow-up.
Statistical analysis
In both hormone therapy trials, incidence of hypertension within the two randomization groups was compared using failure-time methods and the intention-to-treat principle. All participants who did not self-report a prior diagnosis of treated hypertension at baseline and were not taking antihypertensive medications were included in the analyses according to their randomized group until their last follow-up information. Hazard ratios (HRs) and 95% CIs were calculated from Cox regression models, stratified by age group, race/ethnicity, and randomization assignment in the concurrent WHI dietary modification trial. Analyses were performed for two time phases: the intervention phase (from randomization until Date of incident hypertension was defined as the date of selfreport of treated hypertension. Event times during the intervention phase were censored at date of death, last follow-up, or termination of the intervention phase (on July 7, 2002 for CEE plus MPA and February 29, 2004 for CEE alone), whichever occurred first. Participants were included in postintervention phase incidence analyses if they were alive, in follow-up, and had not developed hypertension by termination of the intervention.
In subgroup analyses, interactions were tested between randomization assignment and 10 baseline characteristics within the primary Cox model, expanded to include the designated baseline factor, randomization assignment, and interaction term(s). Participants with missing values were omitted from the corresponding analysis.
In sensitivity analyses, the influence of nonadherence to protocol-assigned treatment was examined by censoring events after participants first became nonadherent (i.e., stopped taking study pills, took <80% of study pills, or started nonstudy menopausal hormone therapy [MHT]). Time-varying weights, which were inversely proportional to the estimated probability of continued adherence, were included in the proportional hazards models to adjust for changes in the distribution of sample characteristics during follow-up.
No adjustment for multiple testing was made. For each time phase, one interaction at most was expected to be significant by chance alone. All analyses were done with SAS version 9.3, and figures were drawn with R 2.15. All P values are twosided and P values of 0.05 or less were regarded as significant at the 0.05 level. The WHI study is registered with ClinicalTrials.gov, number NCT00000611.
RESULTS

Baseline characteristics
Baseline demographic and risk factor characteristics of participants in the CEE and CEE plus MPA trials are shown in Table 1 . Of 12 variables examined, only 1 showed a statistically significant difference between intervention and placebo groups. In the CEE trial, women with high cholesterol by self-report or medical history were somewhat more likely to have received placebo.
Women in the CEE alone differed from women in the CEE plus MPA trials. Women in the CEE trial were more likely to be members of racial/ethnic minority groups, to have a greater number of years since menopause onset, to use hormone therapy at or prior to baseline, to be overweight or obese, and to have diabetes than women in the CEE plus MPA trial.
Among women that remained at risk for incident hypertension during the postintervention phase, baseline characteristics remained balanced between randomization groups (see Table, Supplemental Digital Content 1, http://links.lww.com/ MENO/A286). Figure 1A displays the effect of CEE on the primary endpoint of incident hypertension (self-report of physicianprescribed pills for ''high blood pressure or hypertension'') during the intervention phase. Incident hypertension was 18% higher among women assigned to CEE alone than among those assigned to placebo (HR [95% CI] 1.18 [1.09-1.29]), with an absolute excess risk of 103 additional diagnoses of hypertension per 10,000 person-years. The average treatmentassociated increase in systolic blood pressure was 0.68 (0.02-1.33) mm Hg at year 1 (P ¼ 0.04). CEE did not increase average diastolic pressure in the overall cohort.
CEE trial Intervention phase
Of 10 baseline characteristics, only baseline systolic blood pressure modified the risk of developing hypertension while taking estrogen (Fig. 1A) . Women with a baseline systolic blood pressure of less than 120 mm Hg who took estrogen were 32% more likely to report a new hypertension diagnosis or new blood pressure medication use than those who took placebo (HR 1.32, P interaction ¼ 0.04), and the effect of CEE significantly decreased with increasing baseline blood Among participants in the youngest age group (age 50-54 y), the absolute treatment-associated increase in systolic blood pressure at year 1 was 2.05 mm Hg (0.38-3.72). In this age group, women with intact ovaries were more likely to report a new hypertension diagnosis or new blood pressure medication use while taking estrogen than were those with bilateral oophorectomy (HR ¼ 1.56 [1.16-2.09] vs HR ¼ 0.83 [0.52-1.30], respectively), although the three-way interaction was not significant (P interaction ¼ 0.09). Figure 1B displays the effect of CEE alone after the intervention period through planned closeout; the median postintervention follow-up was 5. Figure 2A displays the effect of CEE plus MPA on incident hypertension during the intervention phase. The rate of incident hypertension (self-report of physician-prescribed pills for high blood pressure or hypertension) was 18% higher for women assigned to CEE plus MPA compared with those assigned to placebo (HR 1.18 [1.09-1.27]), with an absolute excess risk of 75 additional diagnoses of hypertension per 10,000 person-years. The average treatment-associated Incident hypertension defined as self-report of hypertension. Incident hypertension defined as self-report of hypertension.
Postintervention phase
ERP trial Intervention phase
1. Baseline characteristics of the WHI CEE trial (N ¼ 6,342) and CEE plus MPA trial (N ¼ 11,673) by randomization arm CEE trial CEE plus MPA
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increase in systolic blood pressure was 0.71 (0.24-1.18) mm Hg at year 1, with no detected effect on diastolic pressure. None of the examined baseline factors significantly modified the association between CEE plus MPA and either incident hypertension or blood pressure change. The HR for the overall effect on the secondary composite endpoint of self-report of hypertension or high blood pressure was 1.11 (1.05-1.17), with similar influence by subgroup (see Figure, Supplemental Digital Content 3a, http://links.lww.com/MENO/A286).
Postintervention phase
The risk of incident hypertension was no longer statistically significant during the postintervention phase (HR 1.02 [0.94-1.10], P ¼ 0.70 (Fig. 2B) ; the median postintervention followup was 2.8 (IQR, 2.8-2.8) years. The treatment-associated risk of hypertension was, however, positively associated with years since menopause onset (P interaction ¼ 0.04); women randomized to CEE plus MPA closer to menopause onset were less likely to develop hypertension during the postintervention period. Similar results were observed for the secondary endpoint of self-report of treated hypertension or high blood pressure (see Figure, Supplemental Digital Content 3b, http://links.lww.com/MENO/A286).
Sensitivity analyses
Censor for noncompliance with study pills
When we accounted for adherence to study pills during the trial (censoring participants who stopped taking study pills, who took less than 80% of prescribed doses, or began taking nonstudy hormone therapy), the effect of hormone therapy on hypertension increased in both trials (CEE, HR 1.25 [1.12-1.40]; CEE plus MPA, HR 1.25 [1.13-1.38]). In addition, the effect modification of the CEE-hypertension association by baseline systolic blood pressure became more marked, with HRs of 1.57 (1.18-2.09), 1.18 (1.01-1.39), and 1.03 (0.85-1.26) for women with systolic pressures of <120, 120 to <140, and 140 mm Hg, respectively.
Exclude participants with baseline blood pressure 140/90 mm Hg
Excluding participants with baseline blood pressure 140/ 90 mm Hg had little influence on the effect of hormone therapy on our primary or composite endpoints. In the CEE trial, the HR increased modestly to 1.26 (1.14-1.39) and 1.23 (1.13-1.33) for the primary and composite endpoints, respectively. For the CEE plus MPA trial, the HR changed slightly to 1.17 (1.06-1.29) and 1.13 (1.06-1.21), respectively.
Examine effect over time of MHT on incident hypertension
Risk modestly increased with duration of MHT use. Specifically, the HR during 0 to <2, 2 to <4, and 4 years after randomization into the CEE trial were 1.03 (0.87-1.21), 1.17 (1.01-1.36), and 1.29 (1.14-1.46), respectively (P trend ¼ 0.03). Likewise, the HRs for the CEE plus MPA trial were 1.10 (0. 96-1.27), 1.17 (1.03-1.32), and 1.25 (1.10-1.42) , respectively (P trend ¼ 0.12).
DISCUSSION
The WHI provides evidence from a large randomized trial that hormone therapy, both CEE plus MPA and CEE alone, increases the risk of developing hypertension in postmenopausal women and that this risk dissipates after discontinuation of hormone therapy.
The effect of hormone therapy on blood pressure was greatest for women who took CEE alone and had baseline systolic blood pressures of less than 120 mm Hg, and diminished among women with higher systolic blood pressure, although this trend could be attributed to chance alone.
Significant increases of systolic blood pressure among older postmenopausal women randomized to 0.625 mg/d of CEE have been consistently observed in large randomized trials. The Heart and Estrogen/Progestin Replacement Study (HERS) trial (n ¼ 2,763) showed a 2 mm Hg increase in mean systolic blood pressure associated with oral CEE plus MPA use. 17 The WHI trials corroborated the unfavorable effect of CEE, with (n ¼ 16,808) or without MPA (n ¼ 10,739), on mean systolic blood pressure, with increases of 1 to 2 mm Hg for both WHI trials. 11 Our present study shows that these ostensibly small increases in mean blood pressure directly translate into increased risk of hypertension, and are therefore clinically relevant.
Importantly, some evidence suggests that an alternate dose, formulation, and route of administration for estrogen may not detrimentally influence blood pressure. In Kronos Early Estrogen Prevention Study (KEEPS), a 4-year randomized trial of 727 younger postmenopausal women, transdermal estradiol or lower doses of oral CEE (0.45 mg/d) taken with cyclical micronized progesterone did not increase blood pressure. 8 Similarly, smaller randomized trials of oral estradiol, Early versus Late Intervention Trial with Estradiol (ELITE) (n ¼ 643) 18 and Estrogen in Prevention of Atherosclerosis Trial (EPAT) (n ¼ 222), 2 found no increase in systolic blood pressure. The Postmenopausal Estrogen/Progestin Interventions Study (PEPI) trial (n ¼ 875), 1 however, reported that CEE (0.625 mg/d), with or without MPA, also did not significantly increase blood pressure in younger women, raising the possibility that the lack of association in the estradiol trials was due not to the hormone formulation or dose but to the younger age of the study participants. There was, however, no significant effect modification of the hormone therapy-blood pressure relation in our study. Also, CEE, with or without MPA, increased the incidence of stroke in the WHI trials across all age groups. 12 Moreover, in a large population-based study, oral but not transdermal hormone therapy was also associated with increased stroke risk regardless of age. 20 The renin-angtiotensin system (RAS) is dose-dependently activated in women who take estrogen containing oral hormone therapy or oral contraceptives, and may be related to its first-pass hepatic metabolism. First-pass hepatic metabolism
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leads to increased production of C-reactive protein and angiotensin II and a reduction in Insulin-like growth factor 1, processes implicated in the pathogenesis of hypertension. 19 Indeed, in both the CEE and CEE plus MPA trials of the WHI, the treatment was associated with these biomarker changes. [20] [21] [22] Increases associated with CEE, in particular, may be caused by its ability to induce a molecular variant of angiotensinogen or renin substrate. 23 Interestingly, one small randomized trial found that, unlike oral hormone therapy, transdermal hormone therapy had no effect on RAS activity in normotensive postmenopausal women. 24 Increases in blood pressure, however, do not occur in all women who take estrogen. Some studies suggest that the effects of estrogen on the RAS may be genetically mediated, with some women less able to compensate for the dosedependent increase in RAS activation that results in higher blood pressure. 25, 26 Genetic susceptibility may provide a way of identifying those for whom use of oral estrogen will raise blood pressure.
We found an overall increase in risk of hypertension in women who were randomized to CEE plus MPA, but unlike the women randomized to CEE alone, we did not find that baseline blood pressure modified that risk. A possible explanation for this discrepancy is that the MPA may have overridden the dose effect of the estrogen in participants who had lower baseline systolic blood pressure. MPA is known to have beneficial effects on the vascular endothelium of postmenopausal women taking estrogen. 27, 28 Although risk of incident hypertension somewhat increased with follow-up during the intervention phase, complementing an earlier report of the nondiminishing influence of CEE, with or without MPA, on mean systolic blood pressure, 11 we found that the risk of hypertension associated with use of CEE or CEE plus MPA dissipated during the postintervention phase.
This study has some limitations. It is possible that women who were randomized to CEE or CEE plus MPA may have been more likely to have had more clinic visits than women who were randomized to placebo. A greater frequency of visits increases the opportunity of capturing a hypertension diagnosis, although the significant increase in mean systolic blood pressure, measured annually at protocol specified visits, did not diminish during the intervention period.
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As previously reported, 13, 16 participants who were randomized to hormones were less likely to be compliant than those randomized to placebo, which could have appreciably biased risk estimates toward the null. Our adherence analysis, however, indicated that this was unlikely, as risk estimates that accounted for compliance were only modestly increased.
CONCLUSIONS
These results indicate that 0.625 mg/d of CEE, with or without MPA, administered orally to older postmenopausal women caused an increased risk in hypertension that dissipated after the intervention ended. When applying the new clinical practice guidelines, 29 clinicians should also consider use of MHT, and CEE in particular, when screening for secondary hypertension. The possibility that transdermal, lower dose, or non-CEE hormone formulations may be less likely to increase blood pressure or stroke risk warrants further study.
